(Q66850608)
Statements
Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemias and other malignancies (English)
C. Jacquillat
M. Weil
M. F. Gemon-Auclerc
V. Izrael
A. Bussel
M. Boiron
1 February 1976